BeiGene Reports P-III (ALPINE) Trial Results of Brukinsa (zanubrutinib) for the Treatment of Chronic Lymphocytic Leukemia
Shots:
- The P-III (ALPINE) trial evaluating Brukinsa (160mg, BID) vs ibrutinib (420mg, qd) in 652 patients with r/r CLL or SLL across EU, the US, China, New Zealand & Australia
- The results showed that patients treated with Brukinsa achieved superior PFS in a final analysis as assessed by IRC and investigator & also showed superiority in ORR, was well tolerated & the safety results were consistent with prior reports
- The sNDA of Brukinsa is currently under the US FDA’s review for adult patients with CLL or SLL with an anticipated PDUFA date of Jan 20, 2023. Brukinsa was approved in 55+ countries and regions, incl. the US, China, the EU, Great Britain, Switzerland, Canada, Australia & additional international markets
Ref: Businesswire | Image: BeiGene
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
